Medivir AB (MVIRb.F) Announces Initiation of the Second Cohort of the Interferon-Free Phase II Study Combining Simeprevir and Sofosbuvir for Hepatitis C Treatment  
12/13/2012 9:53:16 AM

Stockholm, Sweden—Medivir AB (OMX: MVIR), announced today the initiation of cohort 2 in the interferon-free phase II trial combining simeprevir with sofosbuvir (GS7977) based on a safety and efficacy planned interim analysis of cohort 1 including prior null responder HCV genotype 1 infected patients without advanced hepatic fibrosis. Data from the cohort 1 study will be presented at a scientific conference during H1-2013.